Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure

Lung

Volumn 194, Issue 3, 2016, Pages 409-417

  Demir, Melike ^a   Kaya, Halide ^a   Taylan, Mahsuk ^a   Ekinci, Aysun ^a   Yılmaz, Sureyya ^a   Teke, Fatma ^a   Sezgi, Cengizhan ^a   Tanrikulu, Abdullah Cetin ^a   Meteroglu, Fatih ^a   Senyigit, Abdurrahman ^a  

^a DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Asbestos; Biomarkers; Malignant pleural mesothelioma; Soluble mesothelin related peptide; Thioredoxin 1

Indexed keywords

ASBESTOS; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBULIN 3; MESOTHELIN; PEPTIDES AND PROTEINS; SOLUBLE MESOTHELIN RELATED PEPTIDE; SYNDECAN 1; THIOREDOXIN 1; TUMOR MARKER; UNCLASSIFIED DRUG; EFEMP1 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; PEPTIDE; SCLEROPROTEIN; SDC1 PROTEIN, HUMAN; THIOREDOXIN; TXN PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EARLY DIAGNOSIS; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PLEURA PLAQUE; PLEURA THICKENING; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SMOKING; SOIL POLLUTION; THORAX RADIOGRAPHY; TOXIC INHALATION; AGED; AREA UNDER THE CURVE; BLOOD; CASE CONTROL STUDY; MESOTHELIOMA; PLEURA TUMOR;

AGED; AREA UNDER CURVE; ASBESTOS; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; ENVIRONMENTAL EXPOSURE; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GPI-LINKED PROTEINS; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PEPTIDES; PLEURAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SYNDECAN-1; THIOREDOXINS;

EID: 84962164172     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-016-9868-1     Document Type: Article

References (42)

1. Bayram M, Dongel I, Akbas A, Benli I, Akkoyunlu ME, Bakan ND (2014) Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos. Lung 192(1):197–203
2. Santarelli L, Staffolani S, Strafella E et al (2015) Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma. Lung Cancer 90(3):457–464
3. Maeda M, Hino O (2006) Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers. Pathol Int 56(11):649–654
4. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I (2005) Soluble mesothelin-related protein—a blood test for mesothelioma. Lung Cancer 49(Suppl 1):S109–S111
5. Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T (2011) Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma. Clin Chem Lab Med 49(10):1721–1726
6. Canessa PA, Franceschini MC, Ferro P et al (2013) Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology. Cancer Invest 31(1):43–50
7. Rodriguez Portal JA, Rodriguez Becerra E, Rodriguez Rodriguez D et al (2009) Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev 18(2):646–650
8. Arteaga CL (2002) Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7(Suppl 4):31–39
9. Schildgen V, Pabst O, Tillmann RL et al (2015) Low frequency of EGFR mutations in pleural mesothelioma patients, Cologne, Germany. Appl Immunohistochem Mol Morphol 23(2):118–125
10. Gaafar R, Bahnassy A, Abdelsalam I et al (2010) Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma. Lung Cancer 70(1):43–50
11. Argraves WS, Greene LM, Cooley MA, Gallagher WM (2003) Fibulins: physiological and disease perspectives. EMBO Rep 4(12):1127–1131
12. Zhang Y, Marmorstein LY (2010) Focus on molecules: fibulin-3 (EFEMP1). Exp Eye Res 90(3):374–375
13. Mundt F, Heidari-Hamedani G, Nilsonne G, Metintas M, Hjerpe A, Dobra K (2014) Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies. Biomed Res Int 2014:419853
14. Todosi AM, Gavrilescu MM, Anitei GM, Filip B, Scripcariu V (2012) Colon cancer at the molecular level–usefulness of epithelial-mesenchymal transition analysis. Rev Med Chir Soc Med Nat Iasi 116(4):1106–1111
15. Zong F, Fthenou E, Mundt F et al (2011) Specific syndecan-1 domains regulate mesenchymal tumor cell adhesion, motility and migration. PLoS ONE 6(6):e14816
16. Sezgi C, Taylan M, Sen HS et al (2014) Oxidative status and acute phase reactants in patients with environmental asbestos exposure and mesothelioma. Sci World J 2014:902748
17. Cunningham GM, Roman MG, Flores LC et al (2015) The paradoxical role of thioredoxin on oxidative stress and aging. Arch Biochem Biophys 576:32–38
18. Tabata C, Terada T, Tabata R et al (2013) Serum thioredoxin-1 as a diagnostic marker for malignant peritoneal mesothelioma. J Clin Gastroenterol 47(1):e7–e11
19. Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7(10):2958–2970
20. Mitsudomi T, Yatabe Y (2010) Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 277(2):301–308
21. Trupiano JK, Geisinger KR, Willingham MC et al (2004) Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol 17(4):476–481
22. Kovac V, Dodic-Fikfak M, Arneric N, Dolzan V, Franko A (2015) Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma. Radiol Oncol 49(3):279–285
23. Kaya H, Demir M, Taylan M et al (2015) Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma. Asian Pac J Cancer Prev 16(4):1403–1407
24. Pass HI, Levin SM, Harbut MR et al (2012) Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 367(15):1417–1427
25. Saunders S, Jalkanen M, O’Farrell S, Bernfield M (1989) Molecular cloning of syndecan, an integral membrane proteoglycan. J Cell Biol 108(4):1547–1556
26. Orosz Z, Kopper L (2001) Syndecan-1 expression in different soft tissue tumours. Anticancer Res 21(1):733–737
27. Kumar-Singh S, Jacobs W, Dhaene K et al (1998) Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. J Pathol 186(3):300–305
28. Szatmari T, Dobra K (2013) The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumors. Front Oncol 3:310
29. Metintas M, Metintas S, Ak G et al (2008) Epidemiology of pleural mesothelioma in a population with non-occupational asbestos exposure. Respirology 13(1):117–121
30. Roggli VL, Sharma A, Butnor KJ, Sporn T, Vollmer RT (2002) Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. Ultrastruct Pathol 26(2):55–65
31. Kamp DW, Israbian VA, Preusen SE, Zhang CX, Weitzman SA (1995) Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: role of iron-catalyzed free radicals. Am J Physiol 268(3 Pt 1):L471–L480
32. Metintas M, Ozdemir N, Solak M et al (1994) Chromosome analysis in pleural effusions. Efficiency of this method in the differential diagnosis of pleural effusions. Respiration 61(6):330–335
33. Tomasetti M, Amati M, Nocchi L et al (2011) Asbestos exposure affects poly (ADP-ribose) polymerase-1 activity: role in asbestos-induced carcinogenesis. Mutagenesis 26(5):585–591
34. Pelclova D, Fenclova Z, Kacer P, Kuzma M, Navratil T, Lebedova J (2008) Increased 8-isoprostane, a marker of oxidative stress in exhaled breath condensate in subjects with asbestos exposure. Ind Health 46(5):484–489
35. Powis G, Montfort WR (2001) Properties and biological activities of thioredoxins. Annu Rev Biophys Biomol Struct 30:421–455
36. Thompson JK, Westbom CM, MacPherson MB et al (2014) Asbestos modulates thioredoxin-thioredoxin interacting protein interaction to regulate inflammasome activation. Part Fibre Toxicol 11:24
37. Park EK, Thomas PS, Creaney J, Johnson AR, Robinson BW, Yates DH (2010) Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population. Clin Chem Lab Med 48(6):869–874
38. Cui A, Jin XG, Zhai K, Tong ZH, Shi HZ (2014) Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. BMJ Open 4(2):e004145
39. Hollevoet K, Reitsma JB, Creaney J et al (2012) Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 30(13):1541–1549
40. Scherpereel A, Grigoriu B, Conti M et al (2006) Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 173(10):1155–1160
41. Fukuoka K, Kuribayashi K, Yamada S, Tamura K, Tabata C, Nakano T (2013) Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma. Mol Clin Oncol 1(6):942–948
42. Cristaudo A, Bonotti A, Simonini S et al (2011) Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J Thorac Oncol 6(9):1587–1593